Daiichi Sankyo Buy Of 20 Percent More Of India's Zenotech Suspended
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has been ordered by an Indian court to postpone its attempt to buy shares in Zenotech Laboratories, an India-based maker of generic drugs. The court ordered the acquisition attempt suspended until the opposition of some shareholders can be resolved. Daiichi Sankyo has sought to buy 20 percent of Zenotech on its own. It already owns 47 percent through its earlier acquisition of Ranbaxy Laboratories. Minority stakeholders took the case to court challenging the Daiichi Sankyo offer as too low. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.